Multiomic analysis and oncologic outcomes in pancreatic cancer by PIN1 expression.

784 Background: Proline isomerase (PIN1) is a novel investigational target and is associated with desmoplastic stroma, an immunosuppressive tumor immune microenvironment (TIME) and worse outcomes in pancreatic ductal adenocarcinoma (PDAC). However, stromal targeting has shown conflicting evidence, with some studies showing it leads to more aggressive tumors. To further understand the implications of targeting PDAC stroma, we characterized PIN1 expression and its impact on the TIME and survival. Methods: Patients with a primary diagnosis of PDAC and a stage 4 biopsy sequenced with Tempus xT DNA and/or xR whole transcriptome analysis prior to receiving either 1L FOLFIRINOX or gemcitabine + nab-paclitaxel were selected from the Tempus LENS deidentified database (n=1844). Samples were from the liver (L; 49.7%), primary tumor (PT; 26.4%), peritoneum (PT; 12.4%), or non-liver or peritoneal sites (NLP; 11.6%). RNA-sequencing data were corrected for batch and assay effects and then normalized by computing log2(TPM+1) (TPM = transcripts per million). PDAC samples were stratified into quartiles (Q1-Q4; n=461 for each) by PIN1 RNA expression. Immune cell proportions were estimated from RNA (quanTIseq). PD-L1 was assessed by IHC using the 22C3 clone. Cox proportional hazards (CoxPH) models with risk set adjustment were used to test for adjusted associations between PIN1 and real-world overall survival (rwOS). All p-values were uncorrected. Statistical significance was defined as p